Palisade Bio, Inc. (PALI) Doses First Patient in Phase 2b UC Trial

Palisade Bio Inc. (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, evaluating PALI-2108. The trial aims to enroll 204 patients and has 29 U.S. sites active, with global expansion ongoing. Topline results are expected in Q4 2027. PALI-2108 is an investigational oral PDE4 inhibitor prodrug. The company also conducts a Phase 2 study for Crohn’s disease.

Oppenheimer reiterated an Outperform rating and $8.00 price target on Palisade Bio (NASDAQ:PALI) after additional data from UEG Week. The stock is down 49% over six months but has a Strong Buy consensus and targets ranging from $5 to $25. New tissue analyses showed reduced PDE4D expression and signs of tissue remodeling. Phase 2 trials are ongoing, with data expected in 2H27. Other analysts also reiterated or initiated positive ratings.

Palisade Bio (PALI) shares rose 9% after presenting early clinical data for PALI-2108, showing improvements in Crohn's disease patients. The Phase 1b study reported a 47.5% decrease in disease activity and 58.8% reduction in inflammation marker. The company is conducting further Phase 2 trials. PALI stock is currently at $1.46, up from its 52-week range of $1.32-$2.86.

Palisade Bio (NASDAQ:PALI) reported early-stage trial results for PALI-2108, showing reductions in Crohn's disease activity measures in a small, 5-patient study. The drug demonstrated decreases in disease scores and inflammation markers, with mild adverse events. The company is advancing to Phase 2 studies. Results are preliminary and require further validation.

Palisade Bio (PALI) reported early Phase 1b data for PALI-2108, showing reductions in endoscopic activity and fecal calprotectin in Crohn's patients. Phase 2b UC trial is enrolling, and a Phase 2a Crohn's study is starting. The company noted these are early, open-label results.

Palisade Bio (PALI) reported that its experimental drug PALI-2108 showed a 58.8% reduction in a gut inflammation marker in five Crohn's disease patients after 14 days. The Phase 1b study also demonstrated endoscopic improvement and reduced intestinal inflammation. The company is advancing Phase 2b studies for ulcerative colitis and initiating a Phase 2a study for Crohn's disease.